GlassScriptPhysician profile
Hongxiu Luo
NPI 1710352554
$4,133.03
in general payments reported to CMS, 2019-2025
29 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.03 · 2020: $55.16 · 2021: $237 · 2022: $644 · 2023: $739 · 2024: $1,259 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.08 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $991.29 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $531.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.98 | 2021-2024 | Jardiance |
| Medtronic, INC. | $290.79 | 2022-2025 | Minimed 780g |
| Corcept Therapeutics | $270.76 | 2021-2024 | Korlym |
| Dexcom, INC. | $235.06 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $211.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $156.90 | 2022-2025 | |
| Insulet Corporation | $150.42 | 2023-2025 | Omnipod |
| Ambu INC. | $117.87 | 2023 | |
| Intra-Sana Laboratories | $111.11 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ibsa Pharma INC. | $71.40 | 2021-2025 | Tirosint, Flector, Licart |
| Intuity Medical INC | $69.24 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Bayer Healthcare Pharmaceuticals INC. | $58.82 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $58.50 | 2023-2025 | Gvoke Hypopen, Recorlev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $56.53 | 2019-2020 | |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Mannkind Corporation | $46.94 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $40.44 | 2020-2022 | |
| Amryt Pharma Holdings LTD | $37.08 | 2023 | Myalept |
| Amgen INC. | $29.90 | 2024-2025 | Repatha |
| Amneal Pharmaceuticals LLC | $27.93 | 2024-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $27.77 | 2020-2022 | |
| Chiesi USA, INC. | $24.50 | 2025 | Myalept |
| Averitas Pharma INC. | $21.28 | 2025 | Qutenza |
| Exact Sciences Corporation | $20.91 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $18.18 | 2025 | |
| Cequr Corporation | $17.45 | 2022 | |
| Pfizer INC. | $13.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongxiu Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.